HMOX1
HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
Overview
Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Sorafenib and Sunitinib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
- 1 · What it is
HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
- 2 · What goes wrong in cancer
Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron.
- 3 · How drugs use it
No product in this corpus aims at HMOX1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:5013 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09601 (protein name, function text, keywords and locations (REST API)); CIViC gene HMOX1 (1 evidence items, 0 assertions, 2 variants; diseases: Renal Cell Carcinoma (GraphQL API, CC0))
Biology
Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Location: Endoplasmic reticulum membrane (UniProt). Locus 22q12.3 (HGNC).
- Renal cell carcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HMOX1" OR ABSTRACT:"HMOX1" OR TITLE:"heme oxygenase 1" OR ABSTRACT:"heme oxygenase 1" OR TITLE:"Heme oxygenase 1" OR ABSTRACT:"Heme oxygenase 1" OR TITLE:"bK286B10" OR ABSTRACT:"bK286B10" OR TITLE:"HO-1" OR ABSTRACT:"HO-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HMOX1, not a curated reading list.